J. Safra Sarasin Holding AG Takes Position in Vera Therapeutics, Inc. $VERA

Key Points

• J. Safra Sarasin Holding AG has acquired a stake in Vera Therapeutics, Inc., purchasing 29,567 shares valued at approximately $697,000.
• The company has received mixed ratings from analysts, with a consensus rating of "Moderate Buy" and an average target price of $63.00.
• Vera Therapeutics reported a loss of ($1.20) earnings per share, missing analyst expectations and projecting a negative earnings per share of (-2.89) for the current year.

J. Safra Sarasin Holding AG bought a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 29,567 shares of the company's stock, valued at approximately $697,000.

Other institutional investors have also modified their holdings of the company. California State Teachers Retirement System grew its position in shares of Vera Therapeutics by 19.9% in the fourth quarter. California State Teachers Retirement System now owns 40,640 shares of the company's stock valued at $1,719,000 after purchasing an additional 6,749 shares during the period. Trexquant Investment LP grew its position in shares of Vera Therapeutics by 187.1% in the first quarter. Trexquant Investment LP now owns 62,777 shares of the company's stock valued at $1,508,000 after purchasing an additional 40,913 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Vera Therapeutics in the first quarter valued at about $326,000. Bank of New York Mellon Corp grew its position in shares of Vera Therapeutics by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 143,665 shares of the company's stock valued at $3,451,000 after purchasing an additional 1,717 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Vera Therapeutics by 7.9% in the first quarter. Rhumbline Advisers now owns 63,189 shares of the company's stock valued at $1,518,000 after purchasing an additional 4,600 shares during the period. Institutional investors and hedge funds own 99.21% of the company's stock.

Wall Street Analysts Forecast Growth

VERA has been the topic of several research reports. Wolfe Research reissued a "peer perform" rating on shares of Vera Therapeutics in a research note on Monday, August 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Vera Therapeutics in a research note on Saturday, September 27th. Cantor Fitzgerald reissued an "overweight" rating on shares of Vera Therapeutics in a research note on Thursday, September 18th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Vera Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $63.00.

Vera Therapeutics Price Performance

Vera Therapeutics stock opened at $30.14 on Friday. The company's 50 day simple moving average is $23.44 and its 200-day simple moving average is $23.07. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -8.42 and a beta of 1.23. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.61. The company has a debt-to-equity ratio of 0.16, a quick ratio of 17.03 and a current ratio of 17.03.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same quarter last year, the firm earned ($0.62) EPS. As a group, equities research analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.